BBIO (BridgeBio Pharma, Inc.) Stock Financials & Earnings | Market Cap Arena

BBIO (BridgeBio Pharma, Inc.) Stock Financials & Earnings | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

Mkt Cap$14B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$502M

Net Income (TTM)-$729M

EPS (TTM)-$3.79

Free Cash Flow (TTM)-$458M

Gross Margin94.4%

Op. Margin-113.3%

Net Margin-145.3%

FCF Margin-91.1%

P/S Ratio (TTM)27.5x

P/E Ratio (TTM)—

YoY Rev Growth+126.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$2M	$1M	-$126M
Q2 23	$2M	$1M	-$146M
Q3 23	$4M	$3M	-$158M
Q4 23	$2M	$1M	-$177M
Q1 24	$211M	$211M	$343K
Q2 24	$2M	$2M	-$176M
Q3 24	$3M	$2M	-$192M
Q4 24	$6M	$4M	-$226M
Q1 25	$117M	$114M	-$104M
Q2 25	$111M	$107M	-$134M
Q3 25	$121M	$114M	-$145M
Q4 25	$154M	$139M	-$185M

Valuation

Quarter	P/S	P/E
Q1 23	177.3x	—
Q2 23	2430.1x	—
Q3 23	1462.7x	—
Q4 23	1482.4x	—
Q1 24	63.1x	—
Q2 24	62.9x	—
Q3 24	63.3x	—
Q4 24	62.1x	—
Q1 25	108.2x	—
Q2 25	58.5x	—
Q3 25	39.0x	—
Q4 25	27.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$144M	-$144M
Q2 23	-$113M	-$114M
Q3 23	-$145M	-$146M
Q4 23	-$125M	-$125M
Q1 24	-$220M	-$221M
Q2 24	$75M	$72M
Q3 24	-$181M	-$182M
Q4 24	-$195M	-$199M
Q1 25	-$199M	-$201M
Q2 25	-$81M	-$86M
Q3 25	-$110M	-$110M
Q4 25	-$56M	-$61M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$12K
Q2 23	$428K
Q3 23	$431K
Q4 23	$435K
Q1 24	$1M
Q2 24	$2M
Q3 24	$2M
Q4 24	$3M
Q1 25	$2M
Q2 25	$5M
Q3 25	$470K
Q4 25	$5M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+7.8%	-27.0%
Q2 23	-97.8%	-4.0%
Q3 23	+1110.4%	+25.0%
Q4 23	-6.7%	+36.7%
Q1 24	+11461.9%	+64.7%
Q2 24	+32.1%	+20.3%
Q3 24	-33.2%	+20.2%
Q4 24	+237.1%	+29.4%
Q1 25	-44.8%	+4.9%
Q2 25	+4999.9%	+37.8%
Q3 25	+4318.0%	+36.7%
Q4 25	+2521.2%	+46.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$22M	1199.7%
Q2 23	$27M	1656.2%
Q3 23	$23M	552.4%
Q4 23	$37M	2121.8%
Q1 24	$17M	8.1%
Q2 24	$21M	989.6%
Q3 24	$27M	994.2%
Q4 24	$30M	512.2%
Q1 25	$26M	22.2%
Q2 25	$37M	33.7%
Q3 25	$0	0.0%
Q4 25	$35M	22.5%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$93M	$31M
Q2 23	$107M	$36M
Q3 23	$125M	$36M
Q4 23	$130M	$48M
Q1 24	$141M	$66M
Q2 24	$115M	$60M
Q3 24	$120M	$69M
Q4 24	$130M	$95M
Q1 25	$111M	$106M
Q2 25	$111M	$129M
Q3 25	$113M	$138M
Q4 25	$142M	$182M

Revenue Segments

Quarter	License and Service	Product	Royalty
Q1 23	$2M	—	—
Q3 25	$8M	$108M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$433M	$84M	$517M
Q2 23	$302M	$81M	$384M
Q3 23	$505M	$38M	$543M
Q4 23	$376M	$59M	$435M
Q1 24	$475M	$44M	$520M
Q2 24	$547M	$40M	$587M
Q3 24	$266M	$0	$266M
Q4 24	$681M	$0	$681M
Q1 25	$541M	$0	$541M
Q2 25	$749M	$8M	$757M
Q3 25	$643M	$3M	$646M
Q4 25	$570M	$17M	$587M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	153M	+2.2%
Q2 23	161M	+5.2%
Q3 23	163M	+1.7%
Q4 23	174M	+6.8%
Q1 24	179M	+2.4%
Q2 24	188M	+5.0%
Q3 24	189M	+0.5%
Q4 24	189M	+0.5%
Q1 25	190M	+0.4%
Q2 25	191M	+0.2%
Q3 25	191M	+0.0%
Q4 25	197M	+3.5%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 17	—	—
FY 18	—	—
FY 19	$164K	248
FY 20	$21K	385
FY 21	$121K	578
FY 22	$1K	75K
FY 23	$17K	556
FY 24	$306K	725
FY 25	$72K	7K